Business Wire

Zema Global Strengthens Analytics Offering with Acquisition of cQuant.io

1.4.2025 21:58:00 CEST | Business Wire | Press Release

Share

Zema Global, a leading provider of data management and analytics solutions for companies engaged in the energy, commodities and financial sectors, today announced the acquisition of cQuant.io, an industry leader in analytic solutions for energy and commodity companies. The acquisition, supported by Zema Global’s existing investor FTV Capital, marks a significant step in the company’s mission to deliver real-time, enterprise-grade insights that transform how energy and commodity firms operate.

Andrea Remyn Stone, CEO of Zema Global, said: “This is a pivotal moment for Zema Global and for our customers. By bringing cQuant.io into the fold, we are taking a major step toward delivering truly end-to-end data and analytics capabilities. Our combined offering will empower the energy and commodity sectors with the accuracy, speed, and intelligence needed to thrive in today’s dynamic environment.”

This strategic acquisition combines Zema Global’s enterprise data and curve management capabilities with cQuant.io’s advanced analytics platform, enabling customers to make faster, more accurate decisions in highly complex and volatile markets.

The businesses are uniquely complementary, with each providing high performance, cloud-native platforms now capable of spanning the full spectrum of data ingestion, valuation, forecasting, and portfolio optimization.

Under the terms of the agreement, David Leevan, former CEO of cQuant.io, will become President of Zema Global and lead the company’s expansion into advanced analytics. cQuant.io will operate as a wholly owned subsidiary, branded as “A Zema Global Company.”

David Leevan, former CEO of cQuant.io and President of Zema Global, commented: “We’re incredibly excited to be joining forces with Zema Global. The combination of Zema Global’s market-leading data infrastructure with our analytics infrastructure is an incredibly powerful proposition for the market. We’re excited to offer clients a unified solution that meets their evolving needs - from data acquisition through to portfolio and risk optimization.”

Robert Anderson, partner at FTV Capital, commented: “This acquisition comes off the back of a shared vision between Zema Global and cQuant.io to fundamentally reshape the future of energy and commodities decision-making.” Brent Fierro, partner at FTV Capital, added: “We’re immensely proud to support this strategic acquisition, which positions the newly expanded organization as a clear market leader in data-driven insights and operational intelligence.”

The acquisition underscores Zema Global’s commitment to solving key challenges facing energy and commodities firms including growing data complexity and optimizing real-time decisions across global operations. Customers will benefit from enhanced interoperability, faster time-to-insight, and a seamless data-to-analytics workflow across asset classes and geographies.

With more than 200 clients worldwide, Zema Global’s footprint now includes an expanded global analytics team and increased depth in quantitative modeling, asset valuation, renewable forecasting, and hedge optimization. Zema Global and cQuant.io will continue to operate as closely aligned entities - investing in innovation, product development, and global support to deliver trusted, enterprise-grade solutions for the world’s most sophisticated market participants.

Massumi + Consoli and KPMG served as advisors to Zema Global and FTV Capital, and D.A. Davidson and Foley and Lardner LLP served as advisors to cQuant. Financial terms were not disclosed.

About Zema Global

Zema Global Data Corporation is a leading provider of data, analytics and curve solutions, empowering organizations to harness the power of data for informed decision-making and strategic growth. With a commitment to innovation and client success, Zema Global delivers unparalleled value to its global clientele.

About cQuant.io

Founded in 2016, cQuant.io is an industry leader in analytic solutions for energy and commodity companies. Specializing in Total Portfolio Analysis, cQuant’s cloud-native solution simulates all risk factors, forecasts portfolio performance, and optimizes strategies. Its clients include utilities, IPPs, traders, and renewable developers seeking fast, accurate decision-making across their portfolios.

About FTV Capital

FTV Capital is a sector-focused growth equity investment firm that has raised more than $10.2 billion to invest in innovative, high-growth companies across enterprise technology and services and financial technology and services. Founded in 1998, FTV has developed a highly differentiated and disciplined growth equity model, which leverages the firm’s deep domain expertise and thematic investing approach to help portfolio companies accelerate growth. FTV also provides companies with access to its Global Partner Network®, a strategic group of more than 600 executives from many of the world’s leading financial services firms and FTV Propel®, an in-house team of seasoned operational leaders who deliver counsel and resources across a range of critical business functions. For more information, please visit www.ftvcapital.com and follow the firm on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250401686902/en/

Contacts

Media Contacts
Prosek Partners on behalf of FTV Capital
pro-ftvcapital@prosek.com
Phone: 646-818-9051

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye